These findings support earlier work demonstrating the presence of HLA mutations and other components of the MHC-I APM pathway including TAP1 in small cell lung cancer (SCLC) and melanoma cell lines, and B2M in human melanoma tumours [24–26]. This evidence concerns the gene TAP1 and neoplasm.